Sino Biopharm Reports 2025 Annual Results, Revenue Reaches RMB 31.83 Billion
Sino Biopharmaceutical Limited announced its 2025 annual financial results, recording RMB 31.83 billion in revenue and RMB 4.54 billion in profit attributable to owners. The company saw significant growth in its innovative product sales.
Sino Biopharmaceutical Limited disclosed its 2025 annual financial results on Thursday, reporting total revenue of RMB 31.83 billion (approximately USD 4.4 billion). The profit attributable to owners of the parent was RMB 4.54 billion.
The company's performance was bolstered by the marketing approval and launch of four innovative drugs in 2025: Saitanxin (Culmerciclib Capsules), Hernexeos (Zongertinib Tablets), Putanning (Meloxicam Injection (II)), and Anqixin (Recombinant Human Coagulation Factor VIIa N01 for Injection). Sales of these innovative products grew by 26.2% year-on-year, reaching RMB 15.22 billion.
Sino Biopharmaceutical maintained active research and development efforts, operating multiple R&D centers across China. The company has a substantial pipeline, with 39 innovative oncology drug candidates. Numerous drug candidates in oncology and other therapeutic areas are currently in the marketing application phase or clinical trials across various stages.
Furthermore, the company highlighted accelerated sales for several existing oncology innovations and biosimilars in 2025, which significantly contributed to revenue growth. Sino Biopharmaceutical continues to invest in developing new drug formulations and expanding indications for its products.